Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1

Comparative Medicine

Volumn 63, Issue 4, 2013, Pages 331-337

  DiFranco, Kristina M ^a   Kaswala, Rajesh H ^a   Patel, Chandni ^a   Kasinathan, Chinnaswam ^a   Kachlany, Scott C ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; LEUKOTOXIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HOST RANGE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LEUKOCYTE; LEUKOPENIA; LYSOSOME; MOUSE; NONHUMAN; RAT;

ANIMALS; BLOOD PLATELETS; CELL LINE; DISEASE MODELS, ANIMAL; ERYTHROCYTE COUNT; ERYTHROCYTES; EXOTOXINS; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883784409     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM. 2011. Novel type II antiCD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519-4529.
2. Angelopoulou MK, Kontopidou FN, Pangalis GA. 1999. Adhesion molecules in B-chronic lymphoproliferative disorders. Semin Hematol 36:178-197. (Pubitemid 29214072)
3. Cavazzana-Calvo M, Jabado N, Bordigoni P, Michel G, Haddad E, Mechinaud F, Landman-Parker J, Leblanc T, Plouvier E, Baruchel A, Stephan JL, Souillet G, Vilmer E, Wijdenes J, Le Deist F, Fischer A. 1997. In vivo infusion of antiLFA1 and antiCD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high-risk acute lymphoblastic leukaemia. Leuk Lymphoma 28:103-112. (Pubitemid 28067583)
4. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. 1994. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen 1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol 72:198-203. (Pubitemid 24259435)
5. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, Kotelianski V, Gardner H, Nestle FO. 2007. α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13:836-842. (Pubitemid 47038192)
6. Csanaky G, Matutes E, Vass JA, Morilla R, Catovsky D. 1997. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma-leukemias. Leukemia 11:408-415. (Pubitemid 27120991)
7. de Boer OJ, Wakelkamp IM, Pals ST, Claessen N, Bos JD, Das PK. 1994. Increased expression of adhesion receptors in both lesional and nonlesional psoriatic skin. Arch Dermatol Res 286:304-311. (Pubitemid 24223610)
8. Diaz R, Ghofaily LA, Patel J, Balashova NV, Freitas AC, Labib I, Kachlany SC. 2006. Characterization of leukotoxin from a clinical strain of Actinobacillus actinomycetemcomitans. Microb Pathog 40:48-55. (Pubitemid 43221898)
9. DiFranco KM, Gupta A, Galusha LE, Perez J, Nguyen TV, Fineza CD, Kachlany SC. 2012. Leukotoxin (Leukothera®) targets active leukocyte function antigen 1 (LFA1) protein and triggers a lysosomal mediated cell death pathway. J Biol Chem 287:17618-17627.
10. Ding ZM, Babensee JE, Simon SI, Lu H, Perrard JL, Bullard DC, Dai XY, Bromley SK, Dustin ML, Entman ML, Smith CW, Ballantyne CM. 1999. Relative contribution of LFA1 and Mac1 to neutrophil adhesion and migration. J Immunol 163:5029-5038. (Pubitemid 29501271)
11. Elovaara I, Lalla M, Spare E, Lehtimaki T, Dastidar P. 1998. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 51:1703-1708. (Pubitemid 28565256)
12. Fortin JF, Cantin R, Tremblay MJ. 1998. T cells expressing activated LFA1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM1. J Virol 72:2105-2112. (Pubitemid 28100766)
13. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. 1997. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 109:283-288. (Pubitemid 27394638)
14. Gupta A, Le A, Belinka BA, Kachlany SC. 2011. In vitro synergism between LFA1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells. Leuk Res 35:1498-1505.
15. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R, Yagi N, Maeda S, Yagita H, Okumura K, Kasuga M. 1994. Prevention of autoimmune insulin-dependent diabetes in nonobese diabetic mice by antiLFA1 and antiICAM1 mAb. Int Immunol 6:831-838. (Pubitemid 24183317)
16. Hioe CE, Bastiani L, Hildreth JE, Zolla-Pazner S. 1998. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses 14 Suppl 3:S247-S254.
17. Hioe CE, Chien PC Jr, Lu C, Springer TA, Wang XH, Bandres J, Tuen M. 2001. LFA1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 75:1077-1082. (Pubitemid 32037313)
18. + T lymphocytes and increases cell susceptibility to LFA1-targeting leukotoxin (LtxA). PLoS ONE 6:e23202.
19. Horst E, Radaszkiewicz T, Hooftman-den Otter A, Pieters R, van Dongen JJ, Meijer CJ, Pals ST. 1991. Expression of the leucocyte integrin LFA1 (CD11a/CD18) and its ligand ICAM1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia 5:848-853.
20. Hu X, Wohler JE, Dugger KJ, Barnum SR. 2010. β2 integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol 87:397-403.
21. Inghirami G, Wieczorek R, Zhu BY, Silber R, Dalla-Favera R, Knowles DM. 1988. Differential expression of LFA1 molecules in nonHodgkin's lymphoma and lymphoid leukemia. Blood 72:1431-1434. (Pubitemid 18265919)
22. Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
23. Kachlany SC. 2010. Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy. J Dent Res 89:561-570.
24. Kachlany SC, Schwartz AB, Balashova NV, Hioe CE, Tuen M, Le A, Kaur M, Mei Y, Rao J. 2010. Antileukemia activity of a bacterial toxin with natural specificity for LFA1 on white blood cells. Leuk Res 34:777-785.
25. Kevil CG, Hicks MJ, He X, Zhang J, Ballantyne CM, Raman C, Schoeb TR, Bullard DC. 2004. Loss of LFA1, but not Mac1, protects MRL/MpJ-Fas (lpr) mice from autoimmune disease. Am J Pathol 165:609-616. (Pubitemid 38971390)
26. Kinashi T. 2005. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 5:546-559. (Pubitemid 40961332)
27. Koszik F, Stary G, Selenko-Gebauer N, Stingl G. 2010. Efalizumab modulates T cell function both in vivo and in vitro. J Dermatol Sci 60:159-166.
28. Kretowski A, Mysliwiec J, Kinalska I. 1999. The alterations of CD11A expression on peripheral blood lymphocytes-monocytes and CD62L expression on peripheral blood lymphocytes in Graves disease and type 1 diabetes. Rocz Akad Med Bialymst 44:151-159.
29. Kroemer G, Jaattela M. 2005. Lysosomes and autophagy in cell death control. Nat Rev Cancer 5:886-897. (Pubitemid 41746033)
30. Martin S, Hibino T, Faust A, Kleemann R, Kolb H. 1996. Differential expression of ICAM1 and LFA1 versus L-selectin and VCAM1 in autoimmune insulitis of NOD mice and association with both Th1- and Th2-type infiltrates. J Autoimmun 9:637-643. (Pubitemid 26370974)
31. Mengarelli A, Zarcone D, Caruso R, Tenca C, Rana I, Pinto RM, Grossi CE, De Rossi G. 2001. Adhesion molecule expression, clinical features, and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 40:625-630. (Pubitemid 32303251)
32. Mysliwiec J, Kretowski A, Kinalski M, Kinalska I. 1999. CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects. Immunol Lett 70:69-72. (Pubitemid 29443917)
33. Nickoloff BJ. 2000. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc 5:67-73. (Pubitemid 32044092)
34. Perentesis JP, Gunther R, Waurzyniak B, Yanishevski Y, Myers DE, Ek O, Messinger Y, Shao Y, Chelstrom LM, Schneider E, Evans WE, Uckun FM. 1997. In vivo biotherapy of HL60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res 3:2217-2227. (Pubitemid 28133139)
35. Phongpradist R, Chittasupho C, Okonogi S, Siahaan T, Anuchapreeda S, Ampasavate C, Berkland C. 2010. LFA1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des 16:2321-2330.
36. Pinto A, Carbone A, Gloghini A, Marotta G, Volpe R, Zagonel V. 1993. Differential expression of cell adhesion molecules in B-zone small lymphocytic lymphoma and other well-differentiated lymphocytic disorders. Cancer 72:894-904. (Pubitemid 23215280)
37. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. 2010. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the antiLFA1 antibody efalizumab. Am J Transplant 10:1870-1880.
38. Reuss-Borst MA, Klein G, Waller HD, Muller CA. 1995. Differential expression of adhesion molecules in acute leukemia. Leukemia 9:869-874.
39. + T cells in primary biliary cirrhosis. Dig Dis Sci 47:1209-1215.
40. Simpson DL, Berthold P, Taichman NS. 1988. Killing of human myelomonocytic leukemia and lymphocytic cell lines by Actinobacillus actinomycetemcomitans leukotoxin. Infect Immun 56: 1162-1166.
41. Stenderup K, Rosada C, Dam TN, Salerno E, Belinka BA, Kachlany SC. 2011. Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. J Invest Dermatol 131:2033-2039.
42. Tardif MR, Gilbert C, Thibault S, Fortin JF, Tremblay MJ. 2009. LFA1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T20. Antimicrob Agents Chemother 53:4656-4666.
43. + T cells by human immunodeficiency virus type 1. J Virol 79:13714-13724.
44. Tsai CC, McArthur WP, Baehni PC, Hammond BF, Taichman NS. 1979. Extraction and partial characterization of a leukotoxin from a plaque-derived gram-negative microorganism. Infect Immun 25:427-439. (Pubitemid 9226058)
45. Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, Adams AB, Sears MH, Bowen PH, Kirk AD, Pearson TC, Larsen CP. 2010. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 10:2082-2091.
46. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. 2009. Psoriasis - an autoimmune disease caused by molecular mimicry. Trends Immunol 30:494-501.
47. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, van de Winkel JG. 2003. Resolution of psoriasis upon blockade of IL15 biological activity in a xenograft mouse model. J Clin Invest 112:1571-1580. (Pubitemid 38056283)
48. Walz G, Zanker B, Brand K, Waters C, Genbauffe F, Zeldis JB, Murphy JR, Strom TB. 1989. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci USA 86:9485-9488. (Pubitemid 20010451)
49. Wu H, Rodgers JR, Perrard XY, Perrard JL, Prince JE, Abe Y, Davis BK, Dietsch G, Smith CW, Ballantyne CM. 2004. Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T cell response and T cell phenotypic changes. J Immunol 173:297-306. (Pubitemid 38797354)
50. Yamaguchi N, Kieba IR, Korostoff J, Howard PS, Shenker BJ, Lally ET. 2001. Maintenance of oxidative phosphorylation protects cells from Actinobacillus actinomycetemcomitans leukotoxin-induced apoptosis. Cell Microbiol 3:811-823. (Pubitemid 33133477)
51. Yonekawa K, Harlan JM. 2005. Targeting leukocyte integrins in human diseases. J Leukoc Biol 77:129-140. (Pubitemid 40315046)
52. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. 2002. Inhibition of LFA1-ICAM1 and VLA4-VCAM1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22:146-167. (Pubitemid 34160583)
53. Zeigler M, Chi Y, Tumas DB, Bodary S, Tang H, Varani J. 2001. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate. Lab Invest 81:1253-1261. (Pubitemid 32911974)